The decision to buy your practice gets made in a room you will never see, by people you will never meet, based on a memo you will never read. Most sellers don’t know this room exists.
For four years I built and ran the M&A team at one of the country’s largest DSOs, across more than 50 transactions and over $500 million in deal value. My team prepared the deals that went into that room: I ran the diligence reviews, decided which proposed add-backs earned credit and which didn’t, and worked directly with the selling doctors through the whole process. And when the committee sent back its questions, its conditions, and its repricings, we were the ones who answered them. You learn exactly what a room asks when you spend four years answering it. Almost nothing published for practice owners describes any of this, which is strange, because it is the single most consequential meeting in your sale.
So this post describes it. What the investment committee is, who sits on it, and what a DSO investment committee actually asks before it approves, reprices, or passes on a practice. If you’re earlier in the process and want the full picture of how a sale works end to end, start with our complete guide to selling your dental practice and come back to this.
The short answer, before the detail: an investment committee asks five questions. Is the EBITDA real? What happens when the doctor leaves? Why is this owner selling? Does the practice fit the platform? And what does it look like in three years? The language shifted from deal to deal, but every deal my team prepared was built to answer those five, and nearly every question that came back out of that room traced to one of them. The deals that closed cleanly were the ones where the memo answered all five before anyone had to ask.
The Committee Is Not the Business Development Team
Sellers tend to picture the DSO as one entity with one opinion. Inside, there are two distinct groups, and confusing them costs you.
The business development team is who you meet. They source the deal, build the financial model, negotiate the letter of intent, and manage the relationship. They also run the verification behind it: analysts going through your financials line by line, and on most deals of any size, an outside quality of earnings firm behind them. At the largest DSOs those are separate deal and diligence functions; at leaner groups the same few people wear every hat. Either way, this team is, in a real sense, your advocate inside the building. They get paid to close deals, and by the time they have spent months on yours, they want it to happen. But their name is on the memo, so the verification is real. I’ve written elsewhere about what that review does to an add-back list: the short version is that it tests every number you’ve claimed.
The investment committee approves. Senior executives, typically finance, operations, and clinical leadership, and at private-equity-backed DSOs often someone representing the sponsor, meet to decide which deals get capital. They haven’t visited your practice. Most have never heard your name. They are reading a memo and deciding whether your practice is a better use of the organization’s capital than every other practice in the pipeline that quarter.
That last point is the one sellers never hear: you are not being measured against a checklist. You are being measured against the other deals on the table that day.
You Are Not in the Room. Your Memo Is.
Everything the committee knows about your practice arrives in a deal memo: an overview of the practice, the adjusted EBITDA bridge, the provider situation, payer mix, the integration plan, and a risks section that gets read more carefully than everything else combined.
That document decides more than the negotiation does. Every file you hand over, every question you answer quickly or slowly, every inconsistency between your P&L and your story: all of it becomes raw material for the memo. When your answers are organized and consistent, the memo reads confident. When they’re not, the analyst hedges. Hedged sentences become committee questions, and committee questions become conditions, holdbacks, or price adjustments. You are effectively co-authoring a document you’ll never see, and most sellers write their half badly without knowing it.
The First Question Is Never About the Dentistry
Committees assume the clinical quality was screened before the deal got anywhere near them. What they interrogate is whether the earnings are real and whether they survive the one change the deal guarantees: you, the owner, becoming an employee with an exit date.
These are the five questions that decided the deals I worked on. Different committees wear different language, but every question my team fielded from that room traced back to one of these.
- “Is the EBITDA real?” Not what the P&L says, but what survives diligence. The committee wants to know the quality of earnings status, which add-backs are defensible, and whether owner compensation has been normalized. A practice whose adjusted EBITDA depends on aggressive add-backs reads as a practice whose price is about to change, and committees discount accordingly. This question alone is why the add-back conversation starts long before the committee meets.
- “What happens when the doctor leaves?” The biggest one. If the owner produces most of the dentistry, the committee is buying a job that’s about to be vacated, not a business. They want to know how long you’ll commit post-close, what your production concentration looks like, whether there’s an associate who stays, and how hard your patient relationships are to transfer. More deals struggle in committee over provider durability than over any financial line item.
- “Why is this owner selling?” Motivation is a risk signal. An owner de-risking toward a planned retirement in three to five years reads one way. An owner who sounds burned out, whose hygiene days are shrinking, whose best staff just left, reads another way entirely, because the committee knows the practice they’re modeling may already be past its peak. Sellers are rarely asked this directly. It gets answered anyway, through the numbers and through everything the business development team has observed.
- “Does it fit?” Geography relative to the existing platform, payer mix relative to the operating model, size relative to the integration budget. A strong practice can be a poor fit, and fit questions are the ones a seller can least control, which is exactly why a seller should be talking to more than one kind of buyer in the first place. Fit rejections say nothing about your practice and everything about their map.
- “What does year three look like?” The committee isn’t buying your last twelve months; it’s buying the next several years. Is there capacity to add a provider? Room in the schedule? A hygiene program with headroom? A practice with a credible growth story, even a modest one, reads very differently from a practice that has plateaued at the owner’s personal capacity ceiling.
What Reprices a Deal, and What Kills It
The distinction matters, because sellers hear both outcomes as rejection when only one of them is.
Repricing is the routine outcome of failed verification: add-backs that didn’t survive, owner comp normalized downward, working capital assumptions corrected. Painful, but mechanical, and largely preventable with preparation before going to market.
Killing is different, and in my experience it traced to a short list: provider risk with no mitigation story, a material inconsistency discovered late (nothing erodes a committee’s confidence faster than a surprise the seller knew about), seller motivation that read as distress, or an integration mismatch that no price could fix. There’s a version of each that’s survivable and a version that isn’t, and the difference is almost always timing. A risk disclosed on day one arrives in the memo with a plan attached. The same risk discovered in week ten arrives as a reason to stop.
The honest version, which nobody enjoys hearing: most deals that die in committee die of conditions that were visible, and fixable, a year before the practice went to market.
What This Means If You're Selling
You can’t attend the committee meeting. But you can decide what the memo says, months before it’s written.
The preparation is unglamorous: financials clean enough that the EBITDA bridge is short, add-backs you can document line by line, a real answer on post-close commitment and associate coverage, a selling story that reads as a plan rather than an escape, and a growth case grounded in your actual schedule and capacity. Every one of those maps to a committee question above. That’s not a coincidence. It’s the whole point of preparing.
This is also, frankly, the argument for representation that has sat on the other side of the table. A process run by someone who spent years answering the committee’s questions gets those answers built into the materials from day one, so the memo gets written the right way the first time. The buyer has done this hundreds of times. Most owners do it once.
If you’re wondering where your practice stands before any buyer starts asking these questions, that’s what our practice valuation is for: a clear-eyed read on your numbers, from the buyer’s perspective, before it counts against you.